Collegium Pharmaceutical (COLL) EBT (2014 - 2026)

Collegium Pharmaceutical's EBT history runs 13 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• On a quarterly basis, EBT rose 500.26% year-over-year to $18.7 million in Q1 2026; TTM through Mar 2026 was $108.2 million, a 66.34% increase from a year earlier, with the FY2025 full-year figure at $92.6 million, down 6.04% from the prior year.
• EBT fell to $18.7 million in Q1 2026 per COLL's latest filing, from $29.0 million in the prior quarter.
• Across five years, EBT topped out at $46.7 million in Q4 2023 and bottomed at -$17.6 million in Q1 2023.
• The 5-year median for EBT is $17.3 million (2024), against an average of $15.1 million.
• Across the five-year window, EBT slumped 202.38% in 2022 and soared 1909.99% in 2023, its largest moves.
• Year by year, EBT stood at -$7.8 million in 2022, then soared by 699.54% to $46.7 million in 2023, then plunged by 63.03% to $17.3 million in 2024, then jumped by 68.14% to $29.0 million in 2025, then tumbled by 35.46% to $18.7 million in 2026.
• Per Business Quant, the three latest COLL EBT figures stand at $18.7 million (Q1 2026), $29.0 million (Q4 2025), and $43.4 million (Q3 2025).